


 $OMB\ \ No.\ 0925\text{-}XXXX;\ Expiration\ Date:\ xx/xx/xxxx$ Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it **displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-xxxx). Do not return the completed form to this address.

SUPPLEMENTAL INVESTIGATOR DATA FORM

Date (MM/DD/YYYY):

Sections 1 – 12: REQUIRED INFORMATION (Collected for all investigators participating in NCI-sponsored clinical trials.)									
Investigator Name (Last, First, Middle, Suffix):					2. Degree(s):	3. NCI Investigator No.:			
4. Date of Birth (MM/YYYY):	5. Provider No. (NPI):			6. Are you curr	rently licensed to practice medicine?	? YES NO			
7. Primary Specialty Practice(s): Check all that a		Board Eligible:	Board Certified:			Board Eligible:	Board Certified:		
Anatomic and/or Clinical Pathology				Obstetrics and	Gynecology				
Clinical Genetics				Orthopedic Sur	gery				
Colon and Rectal Surgery				Otolaryngology	,				
Dermatology				Pediatric Hema	atology-Oncology				
Diagnostic Radiology				Pediatrics					
Family Practice				Psychiatry					
Gastroenterology				Public Health a	and General Preventative Medicine				
Gynecological Oncology				Radiation Onco	ology				
Hematology				Surgery					
Internal Medicine				Surgical Oncol	ogy				
Medical Oncology				Thoracic Surge	ery				
Neurological Surgery				Urology					
Neurology				Other					
8. Have you received training in:	Com	pletion of	this training	is mandatory	y for all NCI-registered inves	stigators.			
"Protection of Human Research Participants"?		YES		MPLETED (MM/Y)	YYY):/				
In sections 9 – 12, use this side to either enter new information or view current information. In sections 9 – 12, use this side to make changes to current information only.						on only.			
9. Office Address: The office address and contact	ct information will	I be used for	receipt of all offi	cial corresponden	ce.				
Institution:				Institution:					
Internal Office:				Internal Offic	ce:				
Street Address:				Street Addre	ess:				
Street Address:				Street Addre	ess:				
City:				City:					
State/Province:				State/Provin	nce:				
Zip/Postal Code:				Zip/Postal C	Code:				
Country:				Country:					
Office Phone No.:				Office Phone	e No.:				
Office FAX No.:				Office FAX I	No.:				
Office E-mail:				Office E-ma	il:				
10. Research Contact: Provide a phone number, suitable for display on a publicly accessible website (e.g., www.cancer.gov), which can be used by a patient to contact the investigator's research staff to inquire about clinical trials approved by their IRB and open for enrollment at their institution.									
Research Contact Phone No.:			Research Contact Phone No.:						





11. Primary Shipping Address: The primary shipping address will be used for receipt of all C	TEP-supplied investigational agents.					
Institution:	Institution:					
Internal Office:	Internal Office:					
Street Address:	Street Address:					
Street Address:	Street Address:					
City:	City:					
State/Province:	State/Province:					
Zip/Postal Code:	Zip/Postal Code:					
Country:	Country:					
Shipping Designee: Provide name of shipping designee (preferably a pharmacist) appr	oved to order and receive CTEP-supplied investigational agents.					
Shipping Designee Name:	Shipping Designee Name:					
Shipping Designee Phone No.:	Shipping Designee Phone No.:					
Shipping Designee FAX No.:	Shipping Designee FAX No.:					
Shipping Designee E-mail:	Shipping Designee E-mail:					
NCI USE ONLY: ☐ PSD ☐ SD ☐ IA						
12. Ordering Designee(s): Provide name(s) of ordering designee(s) approved to order CTEP						
CTEP-supplied agent must be signed by either the investigator, the authorized shipping designee must use the primary shipping address (from item #11).	g designee (from item #11), or an ordering designee (from item #12). An ordering					
A. Ordering Designee Name:	A. Ordering Designee Name:					
Ordering Designee Phone No.:	Ordering Designee Phone No.:					
Ordering Designee Fax No.:	Ordering Designee Fax No.:					
Ordering Designee F-mail:	Ordering Designee F ax No Ordering Designee E-mail:					
Ordering Designee E-mail.	Ordering Designee E-mail.					
B. Ordering Designee Name:	B. Ordering Designee Name:					
	• • • <u>————————————————————————————————</u>					
Ordering Designee Phone No.:	Ordering Designee Phone No.:					
Ordering Designee Fax No.:	Ordering Designee Fax No.:					
Ordering Designee E-mail:	Ordering Designee E-mail:					
C. Ordering Designee Name:	C. Ordering Designee Name:					
Ordaring Designed Phone No.						
	Ordering Designee Phone No.:					
Ordering Designee Fax No.:	Ordering Designee Fax No.:					
Ordering Designee E-mail:	Ordering Designee E-mail:					
Please be sure you have also included: 1. Completed FDA Form 1572 with original	signature.					
2. Current Curriculum Vitae (CV).	·					
3. Completed Financial Disclosure Form wi	th original signature.					
I certify that the information on this "Supplemental Investigator Data Form" is true and correct to the best of my knowledge.						
Investigator: Date: Date:						
(Signature)						

Section	INSTRUCTIONS FOR COMPLETING THE "SUPPLEMENTAL INVESTIGATOR DATA FORM"
1.	Investigator Name: Provide legal last name, first name, middle initial or name, and suffix (if applicable).
2.	Degree(s): Provide degree(s) (e.g., M.D., D.O., foreign M.D. equivalent).
3.	NCI Investigator No.: Provide the unique NCI investigator number assigned to the investigator by the Pharmaceutical
	Management Branch (PMB), CTEP, DCTD, NCI at the time of initial registration. (If an investigator has never registered
	to participate in NCI-sponsored clinical trials, leave field blank. An NCI Investigator No. will be assigned by the PMB
	as part of the registration process.)
4.	Date of Birth: Indicate the investigator's date of birth (in MM/YYYY format).
5.	Provider No. (NPI): Indicate the investigator's National Provider Identifier (NPI).
6.	Medical License: Indicate if the investigator is currently licensed to practice medicine.
7.	Primary Specialty Practice(s): Indicate the investigator's primary specialty practice(s). Board Eligibile: Indicate if the investigator is eligible for Board Certification in the primary specialty practice selected.
	Board Certified: Indicate if the investigator is Board Certified in the primary specialty practice selected.
8.	Investigator Training: Indicate if the investigator has completed the NIH-mandated training in the protection of human
0.	research participants, including date completed (in MM/YYYY format). If needed, additional information and online training are
	available at http://phrp.nihtraining.com . The online training takes approximately one hour to complete. <i>Completion of</i>
	protection of human research participants training is mandatory for ALL NCI-registered investigators.
9.	Office Address: The office address will be used for receipt of all official correspondence (e.g., annual registration and
	protocol documents). Include institution, internal office, street, city, state/province, zip/postal code, and country.
	Office Phone No.: Provide daytime phone number at which the investigator can be reached during normal business hours,
	including area code. Investigators from outside the United States should also include the country code.
	Office Fax No.: Provide Fax number at which the investigator usually receives faxes, including area code. Investigators from
	outside the United States should also include the country code.
	Office E-mail: Provide E-mail address at which the investigator usually receives e-mail. This address will be used to send
	information regarding protocols, investigator brochures, stock recovery letters, investigator expiry information, and general
10	information for the investigator.
10.	Research Contact: Provide a phone number, suitable for display on a publicly accessible website (e.g., www.cancer.gov), which can be used by a patient to contact the investigator's research staff to inquire about clinical trials approved by their IRB
	and open for enrollment at their institution.
11.	Primary Shipping Address: The primary shipping address will be used for receipt of all CTEP-supplied investigational
	agents. Include institution, internal office, street, city, state/province, zip/postal code, and country.
	Shipping Designee: Provide name of shipping designee (preferably a pharmacist) approved to order and receive CTEP-
	supplied agents. Note that a "Clinical Drug Request (CDR) Form" for a CTEP-supplied agent must be signed by either
	the investigator, the authorized shipping designee (from item #11), or an ordering designee (from item #12).
	Shipping Designee Phone No.: Provide daytime phone number at which the shipping designee can be reached during
	normal business hours, including area code. Shipping designees from outside the United States should also include the
	country code.
	Shipping Designee Fax No.: Provide Fax number at which the shipping designee usually receives faxes, including area
	code. Shipping designees from outside the United States should also include the country code.
	Shipping Designee E-mail: Provide E-mail address at which the shipping designee usually receives e-mail. This address
12.	will be used to send information regarding protocols, stock recovery letters, and general information for shipping designees. Ordering Designee(s): Provide name(s) of ordering designee(s) approved to order CTEP-supplied agents. Note that a
12.	"Clinical Drug Request (CDR) Form" for a CTEP-supplied agent must be signed by either the investigator, the
	authorized shipping designee (from item #11), or an ordering designee (from item #12). An ordering designee must
	use the primary shipping address (from item #11).
	Ordering Designee Phone No.: Provide daytime phone number at which the ordering designee can be reached during
	normal business hours, including area code. Ordering designees from outside the United States should also include the
	country code.
	Ordering Designee Fax No.: Provide Fax number at which the ordering designee usually receives faxes, including area
	code. Ordering designees from outside the United States should also include the country code.
	Ordering Designee E-mail: Provide E-mail address at which the ordering designee usually receives e-mail. This address
	will be used to send information regarding protocols and general information for ordering designees.